Drug Profile
Favezelimab - Merck Sharp & Dohme
Alternative Names: Mavezelimab - Merck Sharp & Dohme; MK-4280Latest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Haematological malignancies; Non-small cell lung cancer
- No development reported Solid tumours
Most Recent Events
- 15 Mar 2024 Merck Sharp & Dohme completes a phase I trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in Spain, Poland, South Korea, Israel, Germany, China, Canada, USA (IV) (NCT02720068)
- 09 Dec 2023 Efficacy and adverse events data from a phase I/II trial in Haematological malignancies presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Efficacy and adverse events data from a phase I/II trial in Haematological malignancies presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)